WO2017101289A2 - 经导管射频消融系统治疗原发性高血压的用途 - Google Patents

经导管射频消融系统治疗原发性高血压的用途 Download PDF

Info

Publication number
WO2017101289A2
WO2017101289A2 PCT/CN2016/087082 CN2016087082W WO2017101289A2 WO 2017101289 A2 WO2017101289 A2 WO 2017101289A2 CN 2016087082 W CN2016087082 W CN 2016087082W WO 2017101289 A2 WO2017101289 A2 WO 2017101289A2
Authority
WO
WIPO (PCT)
Prior art keywords
ablation
treatment
adipose tissue
tissue
perirenal
Prior art date
Application number
PCT/CN2016/087082
Other languages
English (en)
French (fr)
Inventor
孔祥清
孔有年
Original Assignee
南京广慈医疗科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南京广慈医疗科技有限公司 filed Critical 南京广慈医疗科技有限公司
Priority to US15/574,570 priority Critical patent/US11076911B2/en
Publication of WO2017101289A2 publication Critical patent/WO2017101289A2/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14—Probes or electrodes therefor
    • A61B18/1477—Needle-like probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14—Probes or electrodes therefor
    • A61B18/1492—Probes or electrodes therefor having a flexible, catheter-like structure, e.g. for heart ablation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/12—Diagnosis using ultrasonic, sonic or infrasonic waves in body cavities or body tracts, e.g. by using catheters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00345—Vascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00434—Neural system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00505—Urinary tract
    • A61B2018/00511—Kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00571—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
    • A61B2018/00577—Ablation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636—Sensing and controlling the application of energy
    • A61B2018/00773—Sensed parameters
    • A61B2018/00791—Temperature

Definitions

  • the invention belongs to the field of hypertension treatment, and particularly relates to a use of a transcatheter radiofrequency ablation system for treating essential hypertension.
  • the efficacy of transcatheter radiofrequency ablation for the treatment of inoperable primary tumors and primary tumors with poor radiotherapy and chemotherapy has been recognized by Chinese and foreign medical circles.
  • the thermal ablation generated during treatment is produced by emitting a high frequency current of around 460 kHz.
  • the electrode needle Under the guidance of ultrasound, the electrode needle is inserted into the target tissue, and the inner trocar is pushed open. After the energization, the tissue in the electric field of the electrode needle undergoes ion oscillation, and the temperature of the friction heat increases, which can exceed 100 ° C (the specific temperature can be set according to Automatic adjustment control), and conduction to the surrounding tissue, to produce a spherical ablation stove, so that the tissue target dry coagulation necrosis to achieve therapeutic effect.
  • Essential hypertension is one of the major chronic diseases that currently endanger human health and life, and its incidence is increasing with economic development and life expectancy. According to the 2006 China Cardiovascular Disease Report, the number of hypertensive patients in China has reached 200 million. It is estimated that by 2025, the number of hypertensive patients worldwide will exceed 1.5 billion, of which 300 million will be Chinese.
  • the principle of ROX device surgery is to form a stable ostomy between the arteries and veins by interventional methods, forming a left-to-right shunt at the peripheral blood vessels, reducing the capacity of the arterial system and improving arterial compliance.
  • the preliminary clinical trial of the device has confirmed significant efficacy, but the clinical control trial of the sham operation group has not been performed, and there are more and more serious clinical complications in the postoperative patients, such as hematoma, dissection, venous thrombosis, device shedding. And the situation of right heart capacity overload.
  • Another object of the present invention is to provide a method of treating essential hypertension using a transcatheter radiofrequency ablation system.
  • the object of the invention can be achieved by the following measures:
  • transcatheter radiofrequency ablation systems for the treatment of essential hypertension.
  • the invention treats a secondary center of the system for regulating the activity of the systemic sympathetic system discovered by the inventors through a transcatheter radiofrequency ablation system, reduces the activity of the systemic sympathetic system, thereby lowering the blood pressure level of the hypertensive patients, avoiding the side effects of the oral antihypertensive drugs, and reducing the patients.
  • the risk of cardiovascular complications are not limited to cardiovascular complications.
  • a method for achieving the use of the present invention that is, a transcatheter radiofrequency ablation system for treating essential hypertension is: a needle of a transcatheter radiofrequency ablation system is inserted into a patient with essential hypertension under ultrasound guidance In the lateral perirenal adipose tissue, the electrification begins to ablate. After reaching the ablation temperature and duration, the electrode needle is withdrawn, and then the electrode needle is inserted into the other side of the perirenal fat tissue for ablation.
  • the overall ablation range is bilateral renal peri fat. 1/3 to all of the tissue until the completion of the overall ablation treatment; the target tissue of the ablation treatment is bilateral perirenal adipose tissue.
  • the target tissue is bilateral renal peritoneal fat tissue
  • the preferred target tissue is bilateral subrenal lower adipose tissue
  • the preferred target tissue can be used for therapeutic purposes. It may reduce the damage to adjacent tissues (structures such as kidneys, blood vessels, and ureters) during the treatment process.
  • the target tissue of the ablation treatment is bilateral sub-renal parenchyma
  • the sub-renal parenchyma referred to in the present invention is fat in the peri-renal fat tissue below the lower pole of the kidney. organization.
  • the ablation temperature is from 40 to 70 ° C, especially from 45 to 60 ° C, for a duration of from 5 to 20 seconds, especially from 8 to 15 seconds.
  • the overall ablation range is from 1/3 to 2/3 of the bilateral renal adipose tissue.
  • a specific method for treating essential hypertension using a transcatheter radiofrequency ablation system includes the following steps:
  • CT examination is performed on patients with essential hypertension, and then the results of CT examination are performed by ultrasound multi-section scanning to measure the thickness of the target tissue;
  • the target tissue is bilateral perirenal adipose tissue;
  • the electrode of the transcatheter radiofrequency ablation system is inserted into the positioning point of one side of the perirenal fat tissue and the inner trocar is pushed open, and the ablation is started by energization;
  • the probe is used to observe the position of the electrode needle in the target tissue from multiple directions and multiple locations, so as to correct the needle in time;
  • the transcatheter radiofrequency ablation system is used for ablation of the perirenal adipose tissue on the other side, and the overall ablation range is 1/3 to all of the bilateral perirenal adipose tissue until the overall ablation treatment is completed;
  • an ultrasound scan is performed to observe or detect a bad state in time.
  • step 8 it is possible to observe the presence or absence of fluid accumulation and blood accumulation in the perirenal and abdominal cavities in order to detect complications in time.
  • the inventors discovered a secondary center that regulates the activity of the systemic sympathetic system, reducing the activity of the systemic sympathetic system, thereby reducing the blood pressure level of patients with essential hypertension, and taking antihypertensive drugs for patients. Type and dose reduction or even withdrawal.
  • FIG. 1 is a schematic illustration of a transcatheter radiofrequency ablation system for treating essential hypertension in accordance with the present invention.
  • Figure 2 is a schematic diagram of the lower adipose tissue of the kidney
  • Figure 3 is a graph showing the effect of transcatheter radiofrequency ablation system on the blood pressure of peri-renal adipose tissue in hypertensive model SD rats.
  • the patient was first examined by CT, and then the results of CT examination were performed by ultrasound multi-section scanning to measure the thickness of the lower adipose tissue in the periorbital area to 3.5 cm.
  • the patient was fully anesthetized from the skin with 1% lidocaine.
  • the electrode of the transcatheter radiofrequency ablation system is inserted into the positioning point of the right adipose tissue in the right perirenal region and the inner trocar is pushed open, and the ablation is started by energization, and during the ablation process, the probe is used.
  • the adipose tissue was ablated, and the overall ablation range was about 1/3 of the bilateral perirenal adipose tissue.
  • the overall ablation treatment was completed. After the treatment, the ultrasound was scanned to observe the perirenal fat state.
  • the blood pressure of the clinic was 140/90 mmHg in 1 month, the average blood pressure was 136/90 mmHg in 24 hours, and the blood pressure was 130/85 mmHg in the clinic.
  • the 24-hour average blood pressure was 132/82 mmHg.
  • nifedipine controlled release tablets 90mg / d, valsartan 80mg / d, hydrochlorothiazide 12.5mg / d, metoprolol sustained release tablets 95mg / d, spironolactone 20mg / d, special Lazosin 2 mg / d, office blood pressure 160 / 105 mmHg, 24-hour average blood pressure 150 / 97 mmHg.
  • the patient was first examined by CT, and then the results of CT examination were performed by ultrasound multi-section scanning.
  • the thickness of the semi-peripheral fat tissue was measured to be 5.9 cm.
  • the patient was fully anesthetized from the skin with 1% lidocaine.
  • the electrode of the transcatheter radiofrequency ablation system is inserted into the positioning point of the right adipose tissue in the right perirenal region and the inner trocar is pushed open, and the ablation is started by energization, and during the ablation process, the probe is used.
  • the adipose tissue was ablated.
  • the overall ablation ranged from about 2/3 of the bilateral perirenal adipose tissue.
  • the overall ablation treatment was completed. After the treatment, the ultrasound was scanned to observe the perirenal fat state.
  • the patient's medication was reduced to nifedipine controlled release tablets 30mg / d, irbesartan 150mg / d, metoprolol tablets 25mg / d.
  • the blood pressure of the office was 135/90mmHg
  • the average blood pressure of 24 hours was 128/87mmHg
  • the blood pressure of the clinic was 135/88mmHg
  • the average blood pressure of 24 hours was 130/85mmHg.
  • the electrode of the transcatheter radiofrequency ablation system was inserted into the perirenal lower adipose tissue of the hypertensive model SD rats, and the ablation temperature was reached at 55 ° C for 10 seconds.
  • the electrode needle is retracted, and then the electrode needle is inserted into the other side of the perirenal fat tissue for target ablation.
  • the overall ablation range is about 1/2 of the bilateral perirenal fat tissue until the overall ablation treatment is completed.
  • the blood pressure remained normal and stable after 8 weeks of follow-up, and there was no blood pressure rebound (Fig. 2).
  • the specific target measurement and local anesthesia process are the same as those in Examples 1 and 2.
  • the ablation process is: under the guidance of ultrasound, the electrode of the transcatheter radiofrequency ablation system is inserted into the subrenal parenchyma of the patients with essential hypertension. After the energization begins to ablate, after reaching the ablation temperature of 55 ° C for 10 seconds, the electrode needle is withdrawn, and then the electrode needle is inserted into the other side of the perirenal lower adipose tissue for target ablation.
  • the overall ablation range is bilateral renal adipose tissue. 1/3 to all until the completion of the overall ablation treatment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plasma & Fusion (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Surgical Instruments (AREA)

Description

经导管射频消融系统治疗原发性高血压的用途 技术领域
本发明属于高血压治疗领域，具体涉及一种经导管射频消融系统在治疗原发性高血压方面的用途。
背景技术
经导管射频消融术用以治疗无法手术的原发性肿瘤及放疗、化疗效果差的原发性肿瘤的疗效已得到中外医务界的肯定。治疗时所产生的热消融灶是通过发射460kHz左右的高频电流而产生的。在超声引导下将电极针刺入靶体组织内，推开内套针，通电后电极针电场内的组织发生离子震荡、摩擦生热致温度升高，可超过100℃(具体温度可根据设定自动调节控制)，并传导至周围组织，产生一个球形消融灶，使组织靶体干燥凝固坏死而达到治疗效果。
原发性高血压是目前危害人类健康及生命的重大慢性疾病之一，并且随着经济发展和人均寿命的延长，其发生率越来越高。根据2006年中国心血管病报告，中国的高血压患者数量已达2亿，预计到2025年，全球高血压患者将超过15亿，其中中国患者将达3亿。
原发性高血压的发展过程可从没有症状逐步进展到出现器官损伤。患者在没有症状阶段往往对该疾病的知晓率较低。但在确诊疾病后患者的血压控制达标情况依然不容乐观。虽然中国和美国在各自的高血压指南中均提出了及早降压达标是优化血压管理的基本要求，但据估计，美国高血压患者血压控制达标率只有35％左右，而在中国，该数字仅为8％。所以，高血压的高发生率、低知晓率和低控制率使得高血压并发症患者也日益增多，最主要为卒中(血管栓塞或原位血栓形成)、心衰(收缩型和舒张型)以及进展性肾衰患者，造成了极大的社会及经济负担。
目前原发性高血压的治疗方法主要为长期口服药物治疗。尽管当前可用于治疗高血压的药物种类繁多，但仍有大量患者的血压无法达标。另外，服用大量药物时存在的药物相互作用和副作用往往会影响医师决定是否继续治疗，或是影响患者对治疗方案的依从性。既往研究显示，依从性高、中度及低的高血压患者血压达标率分别为43％、34％和33％。国外的口服降压药物依从性较好的患者比例达50-84％，而国内患者依从性较好的患者比例 仅为30％左右。
所以，如能提供一种非药物治疗方法作为替代治疗，患者、医师和医疗系统均将获益匪浅。目前国际上用于治疗高血压的非药物方法主要为两种，且均为有创型。一是经导管肾动脉去交感神经术(RSD)，二是采用ROX装置行动静脉吻合术。RSD手术的原理是希望通过导管射频消融肾动脉交感神经从而中断高血压和肾脏损害之间的恶性循环，降低血压。新近发布的SYMPLICITY III试验结果显示和假手术组相比，经导管肾动脉去交感神经术手术组患者的高血压控制比例及下降幅度均无明显统计学差异，提示该治疗方法无效。ROX装置手术的原理是在通过介入方法在动静脉之间形成稳定的造瘘，形成外周血管处的左向右分流，降低动脉系统的容量，改善动脉顺应性。目前该装置的初步临床试验证实有显著疗效，但尚未进行假手术组的临床对照试验，且在术后患者存在较多且较严重的临床并发症，如血肿，夹层，静脉血栓形成，装置脱落及右心容量超负荷等情况。
发明内容
本发明的目的是在现有技术的基础上，提供一种经导管射频消融系统在治疗原发性高血压方面的用途。
本发明的另一目的是提供一种采用经导管射频消融系统治疗原发性高血压的方法。
本发明的目的可以通过以下措施达到：
经导管射频消融系统在治疗原发性高血压方面的用途。
本发明是通过经导管射频消融系统处理发明人发现的一个调节全身交感系统活性的次级中枢，降低全身交感系统活性，从而降低高血压患者的血压水平，避免口服降压药物的副作用，降低患者发生心血管并发症的风险。
一种实现本发明用途的方法，即经导管射频消融系统治疗原发性高血压的方法，为：在超声引导下，把经导管射频消融系统的电极针刺入原发性高血压患者的一侧肾周脂肪组织内，通电开始消融，达到消融温度和持续时间后，收回电极针，再将电极针刺入另一侧肾周脂肪组织内进行消融，整体消融范围为双侧的肾周脂肪组织的1/3至全部，直至完成整体消融治疗；该消融治疗的靶体组织为双侧肾周脂肪组织。
在上述治疗过程和方法中，靶体组织为双侧的肾周脂肪组织，优选的靶体组织为双侧的肾周下极脂肪组织，该优选靶体组织可以在实现治疗目的的同时，尽可能地降低治疗过程对临近组织(肾脏、血管及输尿管等结构)的损伤。
在一种优选方案中，消融治疗的靶体组织为双侧的肾周下极脂肪组织，本发明中所指的肾周下极脂肪组织是肾周脂肪组织内位于肾脏下极以下部分的脂肪组织。
在一种优选方案中，消融温度为40～70℃，尤其是45～60℃，持续时间为5～20秒，尤其是8～15秒。
在一种优选方案中，整体消融范围为双侧的肾周脂肪组织的1/3至2/3。
一种具体的采用经导管射频消融系统治疗原发性高血压的方法包括如下步骤：
1)在治疗前，先对原发性高血压患者进行CT检查，然后对照CT检查结果行超声多切面扫查，测量靶体组织的厚度；靶体组织为双侧肾周脂肪组织；
2)根据患者病情制定治疗方案和消融模式及程序；
3)对患者充分局部麻醉从皮肤至消融区；(如采用1％利多卡因)
4)在超声引导下，把经导管射频消融系统的电极针刺入一侧肾周脂肪组织内定位点并推开内套针，通电开始消融；
5)在消融过程中，用探头从多方向、多部位观察电极针在靶体组织内的位置，以便及时纠正补针；
6)达到消融的温度和时间后，收回内套针；
7)按治疗方案采用经导管射频消融系统进行另一侧肾周脂肪组织的消融，整体消融范围为双侧肾周脂肪组织的1/3至全部，直至完成整体消融治疗；
8)治疗完毕后进行超声扫查，以观察或及时发现不良状态。
在步骤8)中可观察肾周及腹腔内有无积液、积血，以便及时发现并发症。
本发明的有益效果：
1)通过经导管射频消融系统处理，发明人发现了一个调节全身交感系统活性的次级中枢，降低全身交感系统活性，从而降低原发性高血压患者的血压水平，使患者服用的降压药物种类及剂量减少甚至停药。
2)通过控制患者的血压和/血糖水平，降低患者发生心血管并发症的风险。
3)通过处理该次级中枢降低全身交感系统活性，降低胰岛素抵抗，降低全身纤维化，可能对于交感神经系统活性异常的其它疾病(如心源性猝死，各种室性心律失常，心力衰竭等)也有治疗作用。
附图说明
图1是本发明经导管射频消融系统治疗原发性高血压的示意图。
图2是肾周下极脂肪组织示意图
图3是经导管射频消融系统破坏肾周脂肪组织对高血压模型SD大鼠血压的影响。
具体实施方式
以下结合附图和实施例对本发明做进一步说明，但本发明的保护范围并不局限于下述各实施例。
实施例1：治疗轻中度高血压
患者，男性，45岁，术前服用80mg/d缬沙坦情况下，诊室血压150/96mmHg,24小时平均血压145/94mmHg。
在治疗前，先对患者进行CT检查，然后对照CT检查结果行超声多切面扫查，测量肾周下极脂肪组织部位厚度为3.5cm；用1％利多卡因对患者充分局部麻醉从皮肤至消融区；在超声引导下，把经导管射频消融系统的电极针刺入右侧肾周下极脂肪组织内定位点并推开内套针，通电开始消融，并在消融过程中，用探头从多方向、多部位观察电极针在肾周脂肪组织内的位置，以便及时纠正补针；监控局部温度达到55℃持续10秒钟后，收回内套针；按治疗方案采用经导管射频消融系统进行另一侧肾周下极脂肪组织消融，整体消融范围为双侧肾周脂肪组织的1/3左右，完成整体消融治疗；治疗完毕后进行超声扫查观察肾周脂肪状态。
接受治疗后,患者停用降压药物。1个月随访诊室血压140/90mmHg,24小时平均血压136/90mmHg,6个月随访，诊室血压130/85mmHg,24小时平均血压132/82mmHg。
实施例2：治疗重度高血压
患者，男性，65岁，术前服用硝苯地平控释片90mg/d,缬沙坦80mg/d,氢氯噻嗪12.5mg/d,美托洛尔缓释片95mg/d，螺内酯20mg/d，特拉唑嗪2mg/d，诊室血压160/105mmHg，24小时平均血压150/97mmHg。
在治疗前，先对患者进行CT检查，然后对照CT检查结果行超声多切面扫查，测量肾周下极脂肪组织部位厚度为5.9cm；用1％利多卡因对患者充分局部麻醉从皮肤至消融区；在超声引导下，把经导管射频消融系统的电极针刺入右侧肾周下极脂肪组织内定位点并推开内套针，通电开始消融，并在消融过程中，用探头从多方向、多部位观察电极针在肾周脂肪组织内的位置，以便及时纠正补针；监控局部温度达到60℃持续10秒钟后，收回内套针；按治疗方案采用经导管射频消融系统进行另一侧肾周下极脂肪组织消融，整体消融范围为双侧肾周脂肪组织的2/3左右，完成整体消融治疗；治疗完毕后进行超声扫查观察肾周脂肪状态。
接受治疗后，患者服用药物减少为硝苯地平控释片30mg/d,厄贝沙坦150mg/d，美托洛尔片25mg/d。随访1月,诊室血压135/90mmHg,24小时平均血压128/87mmHg.6个月随访诊室血压135/88mmHg,24小时平均血压130/85mmHg。
实施例3：动物及人体试验
我们已实施30例动物试验及10例人体试验。
动物试验中，在超声引导下，把经导管射频消融系统的电极针刺入高血压模型SD大鼠的肾周下极脂肪组织内，通电开始消融，达到消融温度55℃持续10秒钟后，收回电极针，再将电极针刺入另一侧肾周下极脂肪组织进行靶点消融，整体消融范围为双侧肾周脂肪组织的1/2左右，直至完成整体消融治疗。动物试验提示对高血压模型动物(SD大鼠)进行特定治疗后血压在术后1周左右下降至正常范围，随访8周血压保持正常平稳状态，未有血压反弹现象(图2)。
10例初步人体试验中包含难治性高血压，合并有心脑血管并发症的高血压患者。
具体的靶点测量和局部麻醉过程同实施例1和2，消融过程为：在超声引导下，把经导管射频消融系统的电极针刺入原发性高血压患者的肾周下极脂肪组织内，通电开始消融，达到消融温度55℃持续10秒钟后，收回电极针，再将电极针刺入另一侧肾周下极脂肪组织进行靶点消融，整体消融范围为双侧肾周脂肪组织的1/3至全部，直至完成整体消融治疗。
术后无一例外的出现血压平稳下降，患者所需服用降压药物种类及剂量明显下降，3例患者可完全停药。目前随访时间已超过6个月，患者血压平稳，未有反弹现象。

Claims (11)

  1. 经导管射频消融系统在治疗原发性高血压方面的用途。
  2. 根据权利要求1所述的用途，其特征在于在超声引导下，把经导管射频消融系统的电极针刺入原发性高血压患者的一侧肾周脂肪组织内，通电开始消融，达到消融温度和持续时间后，收回电极针，再将电极针刺入另一侧肾周脂肪组织内进行消融，整体消融范围为双侧的肾周脂肪组织的1/3至全部，直至完成整体消融治疗；该消融治疗的靶体组织为双侧肾周脂肪组织。
  3. 根据权利要求1所述的用途，其特征在于所述靶体组织为双侧肾周下极脂肪组织。
  4. 根据权利要求1所述的用途，其特征在于所述消融温度为40～70℃，尤其是45～60℃，持续时间为5～20秒，尤其是8～15秒。
  5. 根据权利要求1所述的用途，其特征在于整体消融范围为双侧肾周脂肪组织的1/3至2/3。
  6. 根据权利要求1所述的用途，其特征在于在治疗前，先对患者进行CT检查，然后对照CT检查结果行超声多切面扫查，测量靶体组织的厚度，根据患者病情制定治疗方案和消融模式及程序，对患者充分局部麻醉从皮肤至消融区，然后在超声引导下，把经导管射频消融系统的电极针刺入一侧肾周脂肪组织内并推开内套针，通电开始消融，在消融过程中用探头从多方向、多部位观察电极针在肾周脂肪组织内的位置以便及时纠正补针；达到消融的温度40～70℃和时间后，将电极针收回内套针，然后按治疗方案进行靶体组织另一侧肾周脂肪组织的消融，整体消融范围为双侧肾周脂肪组织的1/3至全部，直至完成整体消融治疗；治疗完毕后进行超声扫查以观察或及时发现不良状态。
  7. 一种经导管射频消融系统治疗原发性高血压的方法，其特征在于在超声引导下，把经导管射频消融系统的电极针刺入原发性高血压患者的一侧肾周脂肪组织内，通电开始消融，达到消融温度和持续时间后，收回电极针，或者继续将电极针刺入另一侧肾周脂肪组织内进行靶点消融，整体消融范围为双侧肾周脂肪组织的1/3至全部，直至完成整体消融治疗；该消融治疗的靶体组织为双侧肾周脂肪组织。
  8. 根据权利要求7所述的方法，其特征在于其包括如下步骤：
    1)在治疗前，先对原发性高血压患者进行CT检查，然后对照CT检查结果行超声多切面扫查，测量靶体组织的厚度；
    2)根据患者病情制定治疗方案和消融模式及程序；
    3)对患者充分局部麻醉从皮肤至消融区；
    4)在超声引导下，把经导管射频消融系统的电极针刺入一侧肾周脂肪组织内定位点并推开内套针，通电开始消融；
    5)在消融过程中，用探头从多方向、多部位观察电极针在肾周脂肪组织内的位置，以便及时纠正补针；
    6)达到消融的温度和时间后，收回内套针；
    7)按治疗方案采用经导管射频消融系统进行另一侧肾周脂肪组织的消融，完成整体消融治疗；
    8)治疗完毕后进行超声扫查，以观察或及时发现不良状态。
  9. 根据权利要求7或8所述的方法，其特征在于所述靶体组织为双侧肾周下极脂肪组织。
  10. 根据权利要求7或8所述的方法，其特征在于所述消融温度为40～70℃，尤其是45～60℃，持续时间为5～20秒，尤其是8～15秒。
  11. 根据权利要求7或8所述的方法，其特征在于整体消融范围为双侧肾周脂肪组织的1/3至2/3。
PCT/CN2016/087082 2015-12-17 2016-06-24 经导管射频消融系统治疗原发性高血压的用途 WO2017101289A2 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/574,570 US11076911B2 (en) 2015-12-17 2016-06-24 Application of radiofrequency catheter ablation system to treatment of essential hypertension

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510956065.8 2015-12-17
CN201510956065 2015-12-17

Publications (1)

Publication Number Publication Date
WO2017101289A2 true WO2017101289A2 (zh) 2017-06-22

Family

ID=59055667

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/087082 WO2017101289A2 (zh) 2015-12-17 2016-06-24 经导管射频消融系统治疗原发性高血压的用途

Country Status (2)

Country Link
US (1) US11076911B2 (zh)
WO (1) WO2017101289A2 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3628251A1 (en) * 2018-09-28 2020-04-01 Koninklijke Philips N.V. Ablation therapy planning system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465471B2 (en) * 2009-08-05 2013-06-18 Rocin Laboratories, Inc. Endoscopically-guided electro-cauterizing power-assisted fat aspiration system for aspirating visceral fat tissue within the abdomen of a patient
US8517962B2 (en) * 2009-10-12 2013-08-27 Kona Medical, Inc. Energetic modulation of nerves
US20120029505A1 (en) * 2010-07-30 2012-02-02 Jenson Mark L Self-Leveling Electrode Sets for Renal Nerve Ablation
US10357302B2 (en) * 2011-07-12 2019-07-23 Verve Medical, Inc. Renal nerve denervation via the renal pelvis
US20130035682A1 (en) * 2011-08-02 2013-02-07 Sirius Medicine, Llc Noninvasive Nerve Ablation
US9119600B2 (en) * 2011-11-15 2015-09-01 Boston Scientific Scimed, Inc. Device and methods for renal nerve modulation monitoring

Also Published As

Publication number Publication date
US20180125572A1 (en) 2018-05-10
US11076911B2 (en) 2021-08-03

Similar Documents

Publication Publication Date Title
WO2017101290A2 (zh) 高强度聚焦超声系统在治疗原发性高血压方面的用途
Chen et al. Safety of ultrasound-guided ultrasound ablation for uterine fibroids and adenomyosis: a review of 9988 cases
Gao et al. Radiofrequency ablation for large hepatic hemangiomas: initial experience and lessons
AU2013230781B2 (en) Ovarian neuromodulation and associated systems and methods
US8473071B2 (en) Method of improved vein closure
WO2017101289A2 (zh) 经导管射频消融系统治疗原发性高血压的用途
Wang et al. Clinical practice guideline for image-guided multimode tumour ablation therapy in hepatic malignant tumours
CN107811703A (zh) 治疗顽固性高血压射频消融肾动脉交感神经装置及其方法
US10194979B1 (en) Methods for catheter-based renal neuromodulation
WO2017101287A2 (zh) 经导管射频消融系统预防原发性高血压的用途
Vahldiek et al. Measuring and optimizing results in multipolar RFA: Techniques and early findings in an experimental setting
Huang et al. Treatment of benign prostatic hyperplasia using transurethral split of the prostate with a columnar balloon catheter
Wang The theoretical basis of minimally-invasive and non-invasive medicine: Treatments—Minimize harm to patients
RU2543347C1 (ru) Способ склерозирования ювенильных гемангиом
Gabrhelik et al. Radiofrequency upper thoracic sympathectomy in the treatment of critical upper limb ischemia--a case series.
Sun et al. In vivo experimental study on the effects of fluid in increasing the efficiency of radiofrequency ablation
Sollazzi et al. Suspect carbon dioxide embolism during retroperitoneoscopic adrenalectomy
US10194980B1 (en) Methods for catheter-based renal neuromodulation
Sapelkin et al. Radiofrequency obliteration in treatment of venous angiodysplasia
Yekuo et al. Multipolar radiofrequency ablation in controlling hemorrhage from blunt liver trauma
Zhang et al. [Retracted] Spiral Computed Tomography in the Quantitative Measurement of the Adjacent Structure of the Left Atrial Appendage in Patients with Atrial Fibrillation
RU2499573C1 (ru) Способ лечения карбункулов почки
RU2256468C1 (ru) Способ лечения метастазов в печени, расположенных рядом с крупными сосудами
RU2438595C1 (ru) Способ лечения веногенной эректильной дисфункции
Núñez-Gil et al. Device-Based Therapies for Resistant Hypertension: Implications for the Perioperative Clinician

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 15574570

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16874353

Country of ref document: EP

Kind code of ref document: A2